Table 3 Subgroup analysis of fish oil supplementation and placebo by race
Outcome | No. of studies | Overall effect | Heterogeneity(%) | |
|---|---|---|---|---|
Effect size(95%CI) | p | I2 | ||
FPG | 13 | 0.13(− 0.03,0.28) | 0.11 | 22.5 |
 Asian | 6 | 0.17(− 0.01,0.35) | 0.07 | 18.5 |
 US/European | 7 | 0.05(− 0.24,0.34) | 0.72 | 31.3 |
FINS | 8 | − 0.00(− 0.22,0.21) | 0.98 | 38.3 |
 Asian | 5 | −0.01(− 0.18,0.17) | 0.96 | 0 |
 US/European | 3 | −0.11(− 0.94,0.72) | 0.80 | 76.8 |
HbAc1 | 10 | 0.01(−0.14,0.17) | 0.88 | 0 |
 Asian | 5 | 0.06(− 0.13,0.24) | 0.55 | 0 |
 US/European | 5 | −0.01(− 0.44,0.30) | 0.71 | 34.5 |
HOMA-IR | 8 | −0.02(− 0.18,0.14) | 0.82 | 0 |
 Asian | 5 | −0.02(− 0.20,0.15) | 0.78 | 0 |
 US/European | 3 | −0.02(− 0.48,0.44) | 0.93 | 27.8 |
TG | 15 | −0.40(− 0.53,-0.28) | 0 | 0 |
 Asian | 8 | −0.34(− 0.48,-0.19) | 0 | 0 |
 US/European | 7 | −0.58(− 0.81,-0.34) | 0 | 0 |
TC | 15 | −0.07(− 0.19,0.05) | 0.28 | 0 |
 Asian | 8 | −0.02(− 0.18,0.14) | 0.81 | 15.1 |
 US/European | 7 | −0.21(− 0.44,0.02) | 0.08 | 0 |
HDL cholesterol | 15 | 0.21 (0.05,0.37) | 0.01 | 37.1 |
 Asian | 8 | 0.26 (0.10,0.43) | 0.00 | 20 |
 US/European | 7 | 0.14(−0.20,0.47) | 0.42 | 49.2 |
LDL cholesterol | 15 | 0.02(−0.10,0.14) | 0.72 | 0 |
 Asian | 8 | −0.01(− 0.17,0.15) | 0.91 | 13.8 |
 US/European | 7 | 0.09(−0.14,0.32) | 0.44 | 0 |